• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates

Pavmed

Pavmed completes $4.1m offering

May 4, 2020 By Sean Whooley

Pavmed (NSDQ:PAVM) filed an SEC Form D to confirm the sale of more than $4 million in debt, options, warrants and other rights to acquire securities. The medical device company completed its total offering of approximately $4.1 million, having made its first sale on April 30, according to the filing. It took just one investor to […]

Filed Under: Business/Financial News, Diagnostics, Funding Roundup Tagged With: FDA, Pavmed

Pavmed to resubmit carpal tunnel device 510(k) application

March 9, 2020 By Nancy Crotti

Pavmed (NSDQ:PAVM) said today that it has reapplied for FDA 510(k) clearance for its CarpX device designed to treat carpal tunnel syndrome. In August 2018, the FDA group reviewing the application for CarpX requested that the company resubmit the application because the group hadn’t reached a consensus within the designated review period. The resubmission incorporates data […]

Filed Under: 510(k), Featured, Food & Drug Administration (FDA), Regulatory/Compliance Tagged With: FDA, Pavmed

Pavmed’s Lucid Diagnostics enters clinical trial with U of Penn

March 2, 2020 By Sean Whooley

Pavmed (NSDQ:PAVM) announced today that its majority-owned subsidiary Lucid Diagnostics entered into a clinical trial research agreement with the University of Pennsylvania to observe its EsoCheck esophageal cell collection device. EsoCheck with “collect & protect technology” is designed to offer a less invasive, more efficient and cost-effective alternative to endoscopic biopsies when managing patients with eosinophilic […]

Filed Under: Clinical Trials, Endoscopic, Featured, Otolaryngology/Ear, Nose & Throat (ENT) Tagged With: Lucid Diagnostics, Pavmed, University of Pennsylvania

Pavmed gains FDA breakthrough nod for esophageal pre-cancer test

February 27, 2020 By Nancy Crotti

Pavmed (NSDQ:PAVM) recently announced that its Lucid Diagnostics subsidiary has received FDA breakthrough device designation for its EsoGuard esophageal DNA test. The test uses esophageal samples collected using Lucid’s 510(k)-cleared EsoCheck cell collection device from certain patients at elevated risk for esophageal dysplasia due to chronic gastroesophageal reflux disease (GERD). EsoGuard and EsoCheck are designed to […]

Filed Under: Diagnostics, Featured, Food & Drug Administration (FDA), Oncology Tagged With: FDA, Pavmed

Pavmed back in NASDAQ compliance

January 13, 2020 By Nancy Crotti

Pavmed (NSDQ:PAVM) said today that it has received formal notice from NASDAQ that it has returned to compliance with the stock exchange’s listing rule after 10 consecutive days with a closing bid price of at least $1 per share. NASDAQ warned the company in November that it was in danger of delisting due to poor […]

Filed Under: Business/Financial News, Catheters, Featured, Surgical, Wall Street Beat Tagged With: NASDAQ, Pavmed

Pavmed threatened with stock exchange delisting

November 4, 2019 By Nancy Crotti

Pavmed (NSDQ:PAVM) is in danger of losing its listing on the NASDAQ exchange, according to a report filed with the Securities & Exchange Commission. In August last year, the FDA group reviewing Pavmed’s 510(k) application for its CarpX minimally invasive carpal tunnel release device asked the company to resubmit the application because the group hadn’t reached […]

Filed Under: Business/Financial News, Wall Street Beat Tagged With: FDA, NASDAQ, Pavmed, Securities & Exchange Commission (SEC)

Pavmed touts FIH CarpX study launch in pursuit of FDA 510(k) resubmission

May 21, 2019 By Fink Densford

Pavmed (NSDQ:PAVM) said yesterday that it launched a first-in-human safety study of its CarpX device to support a planned FDA 510(k) resubmission. The CarpX is a percutaneous device designed to allow the operating physician to relieve compression of the median nerve without a surgical incision. The system combines a balloon catheter with bipolar radio-frequency cutting electrodes […]

Filed Under: 510(k), Clinical Trials, Food & Drug Administration (FDA), Regulatory/Compliance Tagged With: Pavmed

ConvaTec taps Bitar as CEO | Personnel Moves – March 26, 2019

March 26, 2019 By Fink Densford

ConvaTec (LON:CTEC) said today it tapped Karim Bitar as its new CEO, set to take the position on September 30. Prior to joining the U.K.-based medtech company, Bitar served as CEO of agricultural biotech company Genus, holding the corner office position for approximately eight years. Before his time with Genus, Bitar spent 15 years in various […]

Filed Under: Business/Financial News, Featured Tagged With: Baxter, Cantel Medical Corp., ConvaTec, Fresenius, Lantheus, micronsolutions, Millstone Medical Outsourcing, Monarch Medical, Pavmed, sonedo

Pavmed plans safety study for CarpX following FDA meeting

January 11, 2019 By Sarah Faulkner

After a meeting with the FDA, Pavmed (NSDQ:PAVM) said that the agency wants to see more clinical testing for the CarpX device before it can make a decision on whether or not to approve the product. In August last year, the FDA group reviewing Pavmed’s 510(k) application for CarpX requested that the company resubmit the application […]

Filed Under: Business/Financial News, Featured, Food & Drug Administration (FDA), Wall Street Beat Tagged With: Pavmed

Pavmed raises $7m in private placement

December 28, 2018 By Sarah Faulkner

Pavmed (NSDQ:PAVM) said this week that it inked a deal to sell a senior secured convertible note of $7.8 million to an institutional investor. The note was sold with an issue discount of $725,000, for gross proceeds to Pavmed of $7 million. Maxim Group, which acted as the placement agent for the transaction, received a 6.5% […]

Filed Under: Business/Financial News, Featured, Funding Roundup, Wall Street Beat Tagged With: Pavmed

FDA wants Pavmed to re-submit for CarpX carpal tunnel device

August 23, 2018 By Sarah Faulkner

The FDA group reviewing the 510(k) application for Pavmed‘s (NSDQ:PAVM) CarpX device wants the company to resubmit the application. The FDA told the company that it had not reached a consensus within the review period set by the agency’s rules. To extend the review process, the FDA recommended that Pavmed resubmit the application. In a […]

Filed Under: 510(k), Food & Drug Administration (FDA), Pain Management, Regulatory/Compliance Tagged With: Pavmed

  • « Go to Previous Page
  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Go to page 4
  • Go to page 5
  • Go to Next Page »

Primary Sidebar

DeviceTalks Weekly

July 1, 2022
Boston Scientific CEO Mike Mahoney on building a corporate culture that drives high growth results
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS